Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study
Objective: The objective of this double-blind, randomised, placebo-controlled, multicentre clinical study was to demonstrate the non-inferiority and safety of the hypericum extract STW3-VI in a once-daily dosage regime in the treatment of moderate depression. During the 6-week treatment phase, the course of depression was documented by use of HAMD (items 1-17), the von Zerssen’s Adjective Mood Scale (BfS) and the CGI scales. The primary objective of this 3-arm design study was to demonstrate the non-inferiority of hypericum extract STW3-VI (900 mg) to the SSRI citalopram (20 mg) and superiority of hypericum over placebo. Methods: Outpatients (N = 388) suffering from moderate depression were enrolled. The safety and tolerability of hypericum extract in comparison to citalopram and placebo was investigated on the basis of CGI, the occurrence of adverse events and the investigation of laboratory parameters and vital signs. Results: From almost identical baseline values of 21.9 ± 1.2 points (hypericum extract), 21.8 ± 1.2 points (citalopram) and 22.0 ± 1.2 points (placebo), the HAMD score was reduced to 10.3 ± 6.4 (hypericum extract), 10.3 ± 6.4 (citalopram) and 13.0 ± 6.9 (placebo), respectively. Based on this data, the statistical significant therapeutic equivalence of hypericum extract STW3-VI to citalopram (p < 0.0001) and the superiority of this hypericum extract over placebo (p < 0.0001) was demonstrated. At the end of treatment 54.2 % (hypericum extract), 55.9 % (citalopram) and 39.2 % (placebo) of the patients were assessed as therapy responders. The secondary efficacy parameters, change in BfS, CGI and amount of therapy responders showed that the hypericum group was not statistically different from the citalopram group, and significantly superior to the placebo group. Significantly more adverse events with ”certain”, ”probable” or ”possible” relation to study medication were documented in the citalopram group (hypericum: 17.2 %, citalopram: 53.2 %, placebo: 30 %). In most cases, the investigators assessed the tolerability of hypericum extract, citalopram and placebo as ”good” or ”very good”. Conclusion: The non-inferiority of hypericum extract as compared to citalopram and the superiority of both active compounds to placebo were demonstrated, as well as a better safety and tolerability of hypericum extract in comparison to citalopram. These results revealed that hypericum extract STW3-VI is a good alternative to chemically defined antidepressants in the treatment of outpatients with moderate depression.
References
1
Bezchlibnyk-Butler K, Aleksic I, Kennedy S H.
Citalopram - a review of pharmacological and clinical effects.
J Psychiatry Neurosc.
2000;
25
241-254
3
Brenner R, Azbel V.
Comparison of an extract of hypericum (LI 160) and Sertraline in the treatment of depression: a double-blind, randomised pilot study.
Clin Ther.
2000;
22
411-419
4
Brockmöller J, Reum T, Bauer S, Kerb R, Hübner W -D, Roots I.
Hypericin and Pseudohypericin: Pharmacokinetics and Effects on Photosensitivity in Humans.
Pharmacopsychiatry.
1997;
30 8Suppl.)
94-101
7
Gastpar M, Singer A, Zeller K.
Efficacy and Tolerability of Hypericum Extract STW3 in Long-Term Treatment with a Once-Daily Dosage in Comparison with Sertraline.
Pharmacopsychiatry.
2005;
38
78-86
12 IC D -10. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10 Revision (in German). Deutsche Institut für medizinische Dokumentation und Information (DIMDI). Published on behalf of Federal Ministry of Health. Version 1.0 Updated August 1994
14
Keller M B.
Citalopram therapy for depression: a review of 10 years of European experience and data from U.S. clinical trials.
J Clin Psychiatry.
2000;
61
896-908
15
Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I.
Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.
Antimicrob Agents Chemother.
1996ep;
40
2087-2093
16
Kessler R C, McGonagle K A, Zhao S, Nelson C B, Hughes M, Eshleman S. et al .
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
Arch Gen Psychiatry.
1994;
51
8-19
19
Lepine J P, Gastpar M, Mendlewicz J, Tylee A.
Depression in the community: the first pan-European study DEPRES (Depression Research in European Society).
Int Clin Psychopharmacol.
1997;
12
19-29
20
Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D.
St John’s wort for depression (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software - an overview and meta-analysis of randomised clinical trials.
BMJ.
1996;
313
253-258
21
Markowitz J S, Donovan J L, DeVane C L, Taylor R M, Ruan Y, Wang J -S. et al .
Effect of St. John’s Wort on drug metabolism by induction of cytochrome P450 3A4 Enzyme.
JAMA.
2003;
290
1500-1504
24
Müller W E, Rolli M, Schäfer C, Hafner U.
Effects of Hypericum Extract (LI160) in Biochemical Models of Antidepressant Activity.
Pharmacopsychiatry.
1997;
30
102-107
27
Philipp M, Kohen R, Hiller K O.
Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks.
BMJ.
1999;
319
1534-1539
29
Rychlik R, Siedentop H, von den Driesch V, Kasper S.
St. John’s wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily.
Fortschr Med Orig.
2001;
119
119-128
30
Schrader E.
Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.
Int Clin Psychopharmacol.
2000;
15
61-68
31
Schulz H -U, Schürer M, Bässler D, Weiser D.
Investigation of the Bioavailability of Hypericin, Pseudohypericin, Hyperforin and the Flavonoids Quercetin and Isorhamnetin Following Single and Multiple Oral Dosing of a Hypericum Extract containing Tablet.
Drug Res.
2005;
55
15-22
32
Schulz H -U, Schürer M, Bässler D, Weiser D.
Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Drug Res.
2005;
55
561-568
34
Schulz V.
Clinical trials with hypericum extracts in patients with depression-results, comparisons, conclusions for therapy with antidepressant drugs.
Phytomedicine.
2002a;
9
468-474
37
Schulz V.
The psychodynamic and pharmacodynamic effects of drugs: A differenciated evaluation of the efficacy of phytotherapy.
Phytomed.
2000;
7
73-81
38 St. John’s Wort (Hypericum perforatum). St. John’s Wort. Quality Control, Analytic and Therapeutic Monograph. American Herbal Pharmacopoeia and Therapeutic Compendium 1997: 1-32
39
Stolk P, Ten Berg M J, Hemels M E, Einarson T R.
Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials.
Ann Pharmacother.
2003;
37
1891-1899
40
Szegedi A, Kohnen R, Dienel A, Kieser M.
Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John’s wort): randomised controlled double blind non-inferiority trial versus paroxetine.
BMJ.
2005;
330 (7490)
503
41
Tylee A, Gastpar M, Lepine J P, Mendlewicz J.
DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee.
Int Clin Psychopharmacol.
1999;
14
139-151
43
Vorbach E U, Hübner W D, Arnoldt K H.
Wirksamkeit und Verträglichkeit des Hypericum-Extraktes LI 160 im Vergleich mit Imipramin.
Nervenheilkunde.
1993;
12
290-296
